APA (7th ed.) Citation

Harbeck, N., Modi, S., Pusztai, L., Ohno, S., Wu, J., Kim, S., . . . Boileau, J. (2025). 291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). Annals of Oncology, 36, S320. https://doi.org/10.1016/j.annonc.2025.08.720

Chicago Style (17th ed.) Citation

Harbeck, N., et al. "291O DESTINY-Breast11: Neoadjuvant Trastuzumab Deruxtecan Alone (T-DXd) or Followed by Paclitaxel + Trastuzumab + Pertuzumab (T-DXd-THP) Vs SOC for High-risk HER2+ Early Breast Cancer (eBC)." Annals of Oncology 36 (2025): S320. https://doi.org/10.1016/j.annonc.2025.08.720.

MLA (9th ed.) Citation

Harbeck, N., et al. "291O DESTINY-Breast11: Neoadjuvant Trastuzumab Deruxtecan Alone (T-DXd) or Followed by Paclitaxel + Trastuzumab + Pertuzumab (T-DXd-THP) Vs SOC for High-risk HER2+ Early Breast Cancer (eBC)." Annals of Oncology, vol. 36, 2025, p. S320, https://doi.org/10.1016/j.annonc.2025.08.720.